Texas jury awards Seagen nearly $42M in Enhertu patent case
AstraZeneca and Daiichi Sankyo put a lot on the line to position Enhertu as the next big breast cancer drug, one that analysts say could reach billions in peak sales. But thanks to a recent jury decision, Seagen will also be reaping some of the spoils.
Daiichi Sankyo owes Seagen $41.8 million, a Texas jury decided on Friday after finding that Enhertu infringed on patents related to Seagen’s antibody-drug conjugate technology. Seagen says it will also request additional royalty payments until the patent expires in 2024.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
